The principle of the therapy is the use of nanoparticles containing iron oxide, which are injected into brain tumor in a procedure similar to a biopsy.
FRANKFURT, Germany & BERLIN--(BUSINESS WIRE)--Nanostart (OTCQX: NASRY) subsidiary MagForce Nanotechnologies AG (FSE: MF6), a leading medical technology company focusing on nanomedicine in oncology, announced that the Charité-Universitätsmedizin Berlin published the establishment of its NanoTherm therapy center for the treatment of recurrent brain tumors.
“I am pleased that we have accomplished this first step in making NanoTherm therapy available to brain tumor patients”
The principle of the therapy is the use of nanoparticles containing iron oxide, which are injected into brain tumor in a procedure similar to a biopsy. The treatment is carried out in a magnetic field applicator (NanoActivator), a machine that produces an alternating magnetic field and is very safe for humans. Through this high frequency magnetic field, the nanoparticles begin to oscillate and heat is produced from directly within the tumor tissue. Depending on the temperature reached and length of treatment, the tumor cells are either directly destroyed or sensitized for the accompanying chemotherapy or radiation. This novel therapy has the potential to improve the survival for patients with recurrent glioblastoma, an especially malignant type of brain tumor.
“I am pleased that we have accomplished this first step in making NanoTherm therapy available to brain tumor patients,” said Dr. Peter Heinrich, CEO of MagForce. “There have been many challenges associated with introducing a completely new therapeutic approach to the medical community; therefore, the initial rollout has taken longer than expected. Our sales team is active throughout Germany and currently in discussion with leading medical institutions to establish additional treatment centers. We are also working to make the therapy internationally available.”
Dr. Andreas Jordan, CSO and founder of MagForce added, “We are pursuing the further development of NanoTherm therapy for the treatment of prostate and pancreatic carcinomas. NanoTherm therapy has enormous therapeutic potential to treat a variety of solid tumors, and we are just at the beginning.”
Marco Beckmann, CEO of Nanostart AG, commented: “Now that our subsidiary MagForce’s therapy is available at the Charité, this marks the start of the long-awaited commercialization of this new type of cancer therapy based on nanotechnology. We congratulate the MagForce team.”
Please read the press release of the Charité here: http://www.charite.de/en/charite/press/press_reports/artikel/detail/charite_etabliert_nanothermR_therapie_bei_rueckfaellen_von_gehirntumoren/
About Nanostart:
Nanostart AG (OTCQX: NASRY), headquartered in the German financial capital of Frankfurt, is the world’s leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary and venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. For further information, please visit www.nanostart.de.
About MagForce Nanotechnologies:
MagForce Nanotechnologies AG is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce Nanotechnologies AG in selected countries. For further information, please visit: www.magforce.de.
About the Charité:
The Charité is one of the largest university hospitals in Europe. Here, 3800 doctors and scientists heal, do research and teach at the top international level. More than half of the German Nobel Prize winners in medicine and physiology come from the Charité, among them Emil von Behring, Robert Koch and Paul Ehrlich. The Charité also has an international reputation for excellence in training. It extends over four campuses with more than 100 clinics and institutes bundled under 17 CharitéCenters. With more than 13,000 employees, the Charité generates about 1.2 billion euros in sales per year and is one of the largest employers in Berlin. For further information, please visit: www.charite.de.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.
